Cargando…

Mechanisms of action underlying the immunotherapeutic activity of Allovectin in advanced melanoma

Allovectin (velimogene aliplasmid) is a cancer immunotherapeutic currently completing a pivotal phase 3 study for metastatic melanoma. Consisting of a bicistronic plasmid encoding both major histocompatibility complex (MHC) class I heavy and light chains (HLA-B7 and β2-microglobulin, respectively) f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Doukas, J, Rolland, A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3499708/ https://www.ncbi.nlm.nih.gov/pubmed/23037806 http://dx.doi.org/10.1038/cgt.2012.69

Ejemplares similares

Cytokines in type 1 diabetes: mechanisms of action and immunotherapeutic targets
por: Lu, Jingli, et al.
Publicado: (2020)

Immunotherapeutic Advances for NSCLC
por: Massafra, Marco, et al.
Publicado: (2021)

Novel Immunotherapeutic Approaches for Neuroblastoma and Malignant Melanoma
por: Morandi, Fabio, et al.
Publicado: (2018)

A Review of Immunotherapeutic Strategies in Canine Malignant Melanoma
por: Almela, Ramón M., et al.
Publicado: (2019)

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
por: Wolchok, Jedd D, et al.
Publicado: (2013)

Immunotherapeutic advances in gastrointestinal malignancies
por: Rao, Devika, et al.
Publicado: (2019)

The Immunotherapeutic Role of Type I and III Interferons in Melanoma and Non-Melanoma Skin Cancers
por: Weir, Sydney A., et al.
Publicado: (2023)

COVID-19 Therapeutics: Use, Mechanism of Action, and Toxicity (Vaccines, Monoclonal Antibodies, and Immunotherapeutics)
por: Chary, Michael, et al.
Publicado: (2023)

Advances in Immunotherapeutics in Pancreatic Ductal Adenocarcinoma
por: Chouari, Tarak, et al.
Publicado: (2023)

The immunosuppressive role of indoleamine 2, 3-dioxygenase in glioblastoma: mechanism of action and immunotherapeutic strategies
por: Hosseinalizadeh, Hamed, et al.
Publicado: (2022)

Recent Advances in Toxoplasma gondii Immunotherapeutics
por: Lim, Sherene Swee-Yin, et al.
Publicado: (2014)

Immunotherapeutic Advancements for Glioblastoma
por: Ampie, Leonel, et al.
Publicado: (2015)

The evolving immunotherapeutic landscape in advanced oesophagogastric cancer
por: Flynn, Michael, et al.
Publicado: (2018)

Current Advances and Future Prospects in Cancer Immunotherapeutics
por: DEDE, Zeynep, et al.
Publicado: (2023)

Peptide Vaccines in Melanoma: Chemical Approaches towards Improved Immunotherapeutic Efficacy
por: Biri-Kovács, Beáta, et al.
Publicado: (2023)

Two Complementarity Immunotherapeutics in Non-Small-Cell Lung Cancer Patients—Mechanism of Action and Future Concepts
por: Wojas-Krawczyk, Kamila, et al.
Publicado: (2021)

Epigenomics and immunotherapeutic advances in pediatric brain tumors
por: Abedalthagafi, Malak, et al.
Publicado: (2021)

Emerging Preclinical Applications of Humanized Mouse Models in the Discovery and Validation of Novel Immunotherapeutics and Their Mechanisms of Action for Improved Cancer Treatment
por: Karnik, Isha, et al.
Publicado: (2023)

Allergic mechanisms and immunotherapeutic strategies /
Publicado: (1997)

Editorial: Advances in Immunotherapeutic Approaches to Tuberculosis
por: Estrada García, Iris, et al.
Publicado: (2021)

Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs
por: Leeneman, Brenda, et al.
Publicado: (2020)

Immune mediated mechanisms of melanocyte destruction: Paving the way for efficient immunotherapeutic strategies against melanoma
por: Speeckaert, Reinhart, et al.
Publicado: (2012)

Immunotherapeutic Approaches for the Treatment of Glioblastoma Multiforme: Mechanism and Clinical Applications
por: Das, Suprava, et al.
Publicado: (2023)

Synthetic glycolipid activators of natural killer T cells as immunotherapeutic agents
por: Carreño, Leandro J, et al.
Publicado: (2016)

Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma
por: Swamydas, Muthulekha, et al.
Publicado: (2022)

Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs
por: Franken, M.G., et al.
Publicado: (2021)

Cellular Mechanisms of Oxidative Stress and Action in Melanoma
por: Venza, Mario, et al.
Publicado: (2015)

Harnessing the immunotherapeutic potential of CDK4/6 inhibitors in melanoma: is timing everything?
por: Lelliott, Emily J., et al.
Publicado: (2022)

Immunology and Immunotherapeutic Approaches for Advanced Renal Cell Carcinoma: A Comprehensive Review
por: Hah, Yoon-Soo, et al.
Publicado: (2021)

Advances in Immunotherapeutic Approaches to Type 1 Diabetes
por: Cudini, Annamaria, et al.
Publicado: (2023)

Ex Vivo Derived Primary Melanoma Cells: Implications for Immunotherapeutic Vaccines
por: Suriano, Robert, et al.
Publicado: (2013)

Beyond Ipilimumab: a review of immunotherapeutic approaches in clinical trials in melanoma
por: Middleton, Gary
Publicado: (2020)

Extremely potent immunotherapeutic activity of a STING agonist in the B16 melanoma model in vivo
por: Corrales, Leticia, et al.
Publicado: (2013)

Immunotherapeutic targeting of HSP90 client proteins in BRAF-inhibitor resistant melanoma
por: Fecek, Ronald J, et al.
Publicado: (2015)

Immunotherapeutic Intervention against Sarcomas
por: Pedrazzoli, Paolo, et al.
Publicado: (2011)

Immunotherapeutic strategies in autoimmune uveitis
por: Papotto, Pedro Henrique, et al.
Publicado: (2014)

Immunotherapeutic Applications of NK Cells
por: Davis, Carter T., et al.
Publicado: (2015)

Potential Immunotherapeutics for Immunosuppression in Sepsis
por: Shin, Jinwook, et al.
Publicado: (2017)

Immunotherapeutic approaches for hepatocellular carcinoma
por: Longo, Vito, et al.
Publicado: (2017)

Immunotherapeutic Approaches for Glioblastoma Treatment
por: Yaghi, Nasser K., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jgntkirmf6pk0u9bhoe2850on6